Literature DB >> 17007342

The effect of various concentrations of human recombinant epidermal growth factor on split-thickness skin wounds.

Joon Pio Hong1, Yun Wha Kim, Heun Don Jung, Kwon Il Jung.   

Abstract

Epidermal growth factor (EGF) is a potent stimulant of epithelialisation. However, topical application of EGF to achieve facilitated re-epithelialisation in partial thickness wounds has been controversial. A total of 10 pigs, each with eight 4 x 4 cm partial thickness wounds, were treated twice a day for 10 days to observe the effect of human recombinant EGF in concentrations of 0.1, 1, 5, 10, 25 ug/g, vehicle only and two controls. The control and the vehicle-only wounds each demonstrated 100% healing time (HT100) of 9.31 +/- 1.34 and 8.5 +/- 1.12 while the wounds treated with EGF ointment with concentrations of 0.1 (HT100 = 6.4 +/- 0.71), 1 (HT100 = 5.2 +/- 0.63), 5 (HT100 = 5.8 +/- 0.85), 10 (HT100 = 7.1 +/- 1.45) and 25 ug/g (HT100 = 7.4 + 0.57) demonstrated significant reduction in time to achieve re-epithelialisation. Among the EGF-treated wounds, the wounds treated with EGF concentrations of 1 and 5 ug/g achieved the fastest re-epithelialisation with evidence of substantial increase in basal keratinocyte activity observed through Ki-67 activity. In conclusion, this article demonstrates the efficacy of human recombinant EGF in facilitating re-epithelialisation of partial thickness wounds with the most efficient healing found in EGF concentrations of 1 and 5 ug/g.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007342      PMCID: PMC7951662          DOI: 10.1111/j.1742-4801.2006.00187.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  21 in total

Review 1.  Cutaneous wound healing.

Authors:  A J Singer; R A Clark
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 2.  Cell biology of wound healing.

Authors:  C J Schaffer; L B Nanney
Journal:  Int Rev Cytol       Date:  1996

Review 3.  The role of growth factors in wound healing.

Authors:  D G Greenhalgh
Journal:  J Trauma       Date:  1996-07

4.  Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.

Authors:  J M Smiell; T J Wieman; D L Steed; B H Perry; A R Sampson; B H Schwab
Journal:  Wound Repair Regen       Date:  1999 Sep-Oct       Impact factor: 3.617

5.  Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.

Authors:  J M Embil; K Papp; G Sibbald; J Tousignant; J M Smiell; B Wong; C Y Lau
Journal:  Wound Repair Regen       Date:  2000 May-Jun       Impact factor: 3.617

6.  Lanolin and epidermal growth factor in healing of partial-thickness pig wounds.

Authors:  M Chvapil; J A Gaines; T Gilman
Journal:  J Burn Care Rehabil       Date:  1988 May-Jun

Review 7.  Growth factor impact on wound healing.

Authors:  S A Servold
Journal:  Clin Podiatr Med Surg       Date:  1991-10       Impact factor: 1.231

8.  Canine distemper virus infection: proliferation of canine footpad keratinocytes.

Authors:  A Gröne; P Engelhardt; A Zurbriggen
Journal:  Vet Pathol       Date:  2003-09       Impact factor: 2.221

9.  Epidermal and dermal effects of epidermal growth factor during wound repair.

Authors:  L B Nanney
Journal:  J Invest Dermatol       Date:  1990-05       Impact factor: 8.551

10.  Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor.

Authors:  Y Barrandon; H Green
Journal:  Cell       Date:  1987-09-25       Impact factor: 41.582

View more
  2 in total

1.  Decellularized scaffolds containing hyaluronic acid and EGF for promoting the recovery of skin wounds.

Authors:  Zhengzheng Wu; Yan Tang; Hongdou Fang; Zhongchun Su; Bin Xu; Yongliang Lin; Peng Zhang; Xing Wei
Journal:  J Mater Sci Mater Med       Date:  2015-01-21       Impact factor: 3.896

2.  Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.

Authors:  In Gyu Hwang; Jung Hun Kang; Sung Yong Oh; Suee Lee; Sung-Hyun Kim; Ki-Hoon Song; Choonhee Son; Min Jae Park; Myung Hee Kang; Hoon Gu Kim; Jeeyun Lee; Young Suk Park; Jong Mu Sun; Hyun Jung Kim; Chan Kyu Kim; Seong Yoon Yi; Joung-Soon Jang; Keunchil Park; Hyo-Jin Kim
Journal:  Support Care Cancer       Date:  2015-06-04       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.